A series of S'-amido derivatives of S-(2".thienyl)-2',3',S'-13-trideoxyuridine were prepared. The cornpounds were tested for their inhibition of cellular DNA polymerase a. and HIV-RT. The succinic fumaric and maleic acid derivatives of S-(2"-thienyl)-2',3',S'-13-trideoxyuridine were investigated. None of the compounds inhibited HIV-RT. The fumaric acid derivative inhibited DNA pol a. with ICec 33 J.!g mr',
Introduction
Nucleoside analogues are among the agents used in the chemotherapy of cancers and viral diseases. The activities are exerted by the triphosphates of the nucleoside analogues, and the phosphorylation occurs via the monoand diphosphates catalysed by a variety of kinases. Several acyclic guanosine analogues with antiherpetic activities have been shown to be selectively activated to monophosphates by kinases from herpes virus, and further phosphorylated to di-and triphosphates by cellular kinases (Johansson, 1993) . For anticancer and anti-HIV nucleoside analogues cellular kinases are involved at all the three phosphorylation levels (Sandstrom and Oberg, 1993; Schinazi, 1993) . This dependence on kinase-mediated phosphorylation for activation may be a limitation, particularly when the nucleoside analogues have poor affinity for nucleoside kinases (Balzarini et a/., 1987; Starnes and Cheng, 1987; Johnson and Fridland, 1989) . Nucleoside triphosphates are relatively unstable compounds, and cannot cross the cell-membranes due to their highly charged nature. It would, therefore, be of interest to develop selective nucleotide mimics which are able to bypass the kinases dependent steps, and which are lipophilic enough to penetrate the cell membranes.
Several reports describe the use of nucleoside monophosphate prodrugs that have been made more lipophilic by preparation of various 5'-O-phosphonates (Henin et el., 1991; McGuigan et a/., 1992; Sergheraert et a/., 1993; McGuigan et a/., 1994; Pannecoucke et a/., 1994) and 5-'O-phosphoramidates (McGuigan et el., 1993a;  McGuigan et a/., 1!;l93b). Nucleoside prodrugs have also been designed by 5'-O-esterification (Aggarwal et a/., 1990; Sharma et el., 1993) .
Several observations support the idea that substrates with a low charge will have affinity for phosphate binding sites (Heifetz et a/., 1979; Suhadolnik, 1990) . There are less ionic groups for phosphate binding in catalytic rather than regulatory sites (Evans et et., 1981) , and lipophilic triphosphate mimics have beeh prepared to function as an enzyme bound nucleotide-metal complex (Otoski and Wilcox, 1988) or as HIV-RT inhibitors (Bjorsns et a/., 1993) .
In previous studies it has been shown that triphosphates of 5-(2"-thienyl) uridine nucleoside analogues inhibit viral and cellular polymerases. The 2'-deoxy analogue has an activity against HIV-RT comparable to that of AZT triphosphate (Johansson et a/., 1990) . The 2',3'-dideoxy analogue is active against HIV-RT, although less so than 2",3'-dideoxythymidine. These 5-(2"-thienyl) uridine analogues are inactive against HIV in cell-culture assays, most probably due to phosphorylation inefficiencies at some stage of the intracellular triphosphate synthesis (Persson et a/., 1994) .
The only drugs approved, so far, for treatment of AIDS are 3'-azido-3'-deoxythymidine (AZT, zidovudine), 2',3'-dideoxycytidine (DOC), 2',3'-dideoxyinosine (001) and 2",3 '-didehydro-2',3 '-dideoxythymidine (D4T).
HIV-1 RT is composed of two subunits, p66 and p51 (Goff, 1990; Jacob-Molina and Arnold, 1991) , and the crystal structure of the HIV-1 RT heterodimer has been determined (Kohlstaedt et a/., 1992; Jacob-Molina et a/., 1993) . The polymerase active site of this enzyme has considerable structural similarity to the polymerase active site of the Klenow fragment of Escherichia coli DNA polymerase 1 (Ollis et el., 1985; Steitz et al., 1987; Kohlstaedt et al., 1992) , and contains three aspartic acids positioned for catalytic binding to Mg 2 + and the nucleoside triphosphate substrate. Recently it has also been shown that the rat DNA polymerase~ (Davies II et al., 1994; has structural similarities in the active site to the polymerase active site of the Klenow fragment mentioned earlier, and that two divalent metal ions may be involved in the catalytic binding (Steitz, 1993; Davies II et al., 1994; Pelletier et al., 1994; Sawaya et al., 1994) . Against this background it was decided to synthesize some 5'-derivatives of 5-(2"-thienyl) uridine compounds which could, presumably, function as simple triphosphate mimics by structural elements which could interact with a divalent metal ion and aspartic acids at the catalytic site of polymerases. Such compounds would be independent of cellular kinases and have a lipophilic character which would enable them to penetrate cells.
Recently, some 5'-esters of thymidine and 5-(2"-thienyl)-2'-~-deoxyuridinehave been prepared (Wellmar, H6rnfeldt, Grbnowitz and Johansson, unpublished data) , which have shown promising activity. In this paper the synthesis of some 5'-amido derivatives of 5-(2"-thienyl)-2',3',5'-~-trideoxyuridine is described ( Fig. 1) (Persson et al., 1994) . In order to prevent possible cleavage of the 5'-a-ester nucleoside, the ester group was replaced with the more stable amido group. The succinic, fumaric and maleic acid derivatives of 5-(2"-thienyl)-2',3',5'-~ trideoxyuridine have been structurally compared to the monomethyl ester of the triphosphate using the Sybyl program.
Results

Chemistry
Commercial uridine was reacted with acetyl bromide in acetonitrile to give a nearly quantitative yield of the bromoacetate 2'-brorno-z -deoxv-a',5'-di-O-acetyluridine (Starret et al., 1990) . The reduction of the bromoacetate with Zn/Cu in methanol (Starret et al., 1990 ) gave three components. From this crude mixture the 2',3'-didehy-~1~1 39 30 DNA pol a (Act CT DNA) *Persson, et al., (1994) .
6b 7 ddT-TP 8*
As mentioned above there are considerable structural similarities between different polymerase active sites.
Since ddC-triphosphate has been cocrystallised with rat 
Inhibition of viral and cellu/ar po/ymerases
Compounds 4-7 were tested for inhibition of cellular DNA polymerase a and HIV-RT, using activated calf thymus DNA as a template primer. 3'-Deoxythymidine was used as a control and the results are summarized in Table 1 . For comparison, data from 5-(2"-thienyl)-2',3'-dideoxyuridine triphosphate (8) (Fig. 2. ) (Persson et a/., 1994) are included. None of the compounds 4-7 inhibited HIV-RT. The fumaramic acid derivative 6b inhibited DNA pol a with IC so 33 fl9 mr',an inhibition similar to those for ddT-TP and compound 8. The succinamic acid derivative 5b was about half as active with IC so 76 fl9 mr'.
method was used for the synthesis of the fumaric acid derivative of the 5-(2"-thienyl)-2',3 ',5'-trideoxyuridine, and the yields of the 5'-ethyl fumaramate (6a) and its corresponding acid (6b) were 52% and 86%, respectively. The 5'-maleamic acid 7 was obtained in 64% yield by direct reaction of the 5' -arnino nucleoside with maleic anhydride.
dro-2',3'-dideoxyuridine was isolated by HPLC using heptane/ethyl acetate/2-propanol 45/45/10 as eluent. The 2',3'-didehydro-2',3'-dideoxyuridine was converted to its corresponding 5'-O-acetyl-2',3' -dideoxyuridine analogue by a catalytic hydrogenation (Chu et a/., 1989) . The protected uridine analogue was iodinated in the 5-position with ceric ammonium nitrate (CAN) and iodine following the method used by Asakura and Robins, (1988) . Pd(O)-catalysed cross-coupling reaction of 5' -Ovacetyl-z ,3'-dideoxy-5-iodo-uridine and 2-tributylstannylthiophene in an inert atmosphere (Persson et a/., 1994) yielded the protected 5' -O-acetyl-2',3' -dideoxy-5-(2" -thienyl) uridine in 58% yield. Removal of the acetyl group was achieved by standard hydrolysis using sodium methoxide in methanol.
The 5'-hydroxyl group was transformed to its corresponding 5 -amme group in three steps. Tosylation of the 5 '-hydroxyl group by tosyl chloride in anhydrous pyridine at 5°C (Harada et a/., 1987) , gave the 2',3'-dideoxy-5'-Otosyl-5-(2'-thienyl)uridine (2) in 73% yield. Reacting the 5'-O-tosyl-5-(2"-thienyl)uridine with lithium azide in anhydrous dimethylformamide (DMF) at 60°C gave the 5' -azido-5-(2"-thienyl)-2',3',5' -trideoxyuridine (3) in 58% yield (Harada et a/., 1987) . Finally, methods for obtaining high yields in the reduction of the 5' -azido to the 5 -amino derivative were investigated. A common and frequently used method is catalytical hydrogenation, but this methodology could unfortunately not be used because of poisoning effect of sulphur on the Pd/C catalyst. Attempted reduction with triphenylphosphine yielded only 10-15% of pure 5'-amino-2',3',5'-trideoxy-5-(2"-thienyl)uridine (4), the low yield was probably due to the troublesome purification. The reported method by Samano and Robins, (1991) , using two equivalents of tributylstannane and a catalytic amount of azobis(isobutyronitrile) (AIBN), did not work with the 5-(2"-thienyl)-substituted nucleoside analogue (and no traces of the 5'-ammo-zB'-dldeoxy analogue could be detected). The Use of sodium borohydride was excluded since one of the side reactions by this method is cleavage of the glycosidic bond, resulting in a low yield. The method used in this paper consisted of reacting the 5'-azido-5-(2' -thienyl)-2',3',5'-trideoxyuridine (3) analogue with hydrogen sulphide (H 2S) in a mixture of pyridine and water 1:1 at room temperature (Gronowitz et a/., 1975; Adachi et a/., 1977) . The reaction conditions were very mild and the desired compound was obtained in over 90% yield.
The 5'-amido derivatives of 5-(2"-thienyl)-2',3',5'-trideoxyuridine were prepared according to Henn et a/., (1993) . The 5'-amino nucleoside was reacted with methyl succinyl chloride and the corresponding 5 -rnethyl succinamate (5a) was obtained in 41% yield. Alkaline hydrolysis of the methyl ester, followed by treatment with Dowex H+, generated the free acid 5b in 78% yield. The same DNA polymerase~it was decided to use this triphosphate conformation for comparison with our triphosphate mimics. The succinic, fumaric and maleic acid derivatives of the 5-(2"-thienyl)-2',3 ',5'-trideoxyuridine were compared with the triphosphate monomethyl ester. Assuming that the nucleoside conformation is about the same when it is bound to the active site, the 5'-CH 2 of the nucleoside is symbolized by a 5 -rnethyl group. To get a triphosphate conformation which has a similarity to the transition state, the bond between the a-phosphorus and the oxygen of the pyrophosphate was elongated by 30% (from 1.5-2.0 A).
The calculations showed that the succinamic acid derivative 5b adopts a conformation where the two carbonylic oxygens fit the a-and the~-phosphates in the triphosphate moiety. The energy difference for the conformation which mimics the diphosphate compared to the conformation energy minimized for the succinic acid derivative is about 5 kcal mer". Attempts to adopt a conformation where the two carbonylic oxygens can overlap both the a-and y-phosphate in the triphosphate units, was more difficult. The carbon chain was shown to be too short to overlap the y-phosphate satisfactory. The fumaramic acid derivative 6b can assume a low energy conformation, where the two carbonylic oxygens fit well to the a-and the y-phosphates in the triphosphate moiety. The maleamic acid derivative 7 is too short and rigid to mimic either the di-or the triphosphate.
It is quite interesting that in this simplistic approach to inhibition of polymerases, the mimicking compounds which show the best and second best fit in the triphosphate modelling are also those which possess activity. However kinetic analysis of the mode of action of these two compounds remains to be carried out.
Materials and Experimental Procedures: Chemistry
Molecular mOdelling and calculations were performed using the Sybyl program. The triphosphate conformation used was the one presented by Pelletier et al., (1994) , with an elongated (2.0 A) bond between the a-phosphorous and the oxygen of the pyrophosphate moiety. The succinic, fumaric and maleic acid derivatives of the 5-(2"-thienyl)-2',3',5'-trideoxyuridine were energy minimized and the resulting conformations were used to create conformations that could mimic the triphosphate. Finally, the energy of the mimicking conformations were calculated and compared to the minimized energies.
Melting points were recorded on a Gallenkamp MFB-595-010 M melting point apparatus and are uncorrected. 1H NMR spectra were recorded on a Varian XL-300 spectrometer.The 1H NMR shifts are given relatively to TMS. The mass spectra were recorded on a Jeol JMS-SX 102 spectrometer. Purification of compound 5a by HPLC was performed on a silica column Nucleosil500x1 O. Tetrahydrofuran (THF) was dried by refluxing and distillation over sodium wire. All other solvents were distilled prior to use.
1-(2,3 '-Dideoxy-S '-O"tosyl-[3 -D-ribofuranosyl)-S-(2 "-thienyl)-uraci/2
To an ice cooled solution of 1-(2',3'-dideoxyribofuranosyl)-5-(2"-thienyl)uracil (1) (1.70 g, 5.78 mmol) in pyridine (130 ml), tosyl chloride (1.65 g, 8.67 mmol) was added. After stirring at 5 DC for 48 h, the reaction mixture was poured onto ice water. The water phase was extracted two times with dichloromethane and the combined organic phases were washed with sodium hydrogen sulphate and water, dried over magnesium sulphate and evaporated to dryness. The resulting syrup was chromatographed on silica gel 60 using dichloromethane/methanol (96:4) as eluent, giving the title compound (1.89 g, 73%). 1H NMR (CDCl s) 0 6.15 (1H, dd, 1-H), 1.98-2.54 (4H, rn, 2ab-H, 3ab-H 
1-(S '-Azido-2:3 ',S '-trideoxy-[3 -D-ribofuranosyl)-S-(2 ": thienyl)-uraci/3
A mixture of 2 (1.90 g, 4.24 mmol) and lithium azide (0.41 g, 8.48 mmol) in (DMF) (33 mL) was heated at 70-75 DC for 3 h and then evaporated to dryness. The residue was triturated with ice cooled water to give a crystalline mass, which was collected by filtration. The crude product was recrystallized from ethanol giving the title compound 
1-(S '-Amino-2 ',3 ',S '-trideoxy'-[3-D-ribofuranosyl)-S-(2'-thienyl)-uraci/4
Hydrogen sulphide was introduced into a solution of 3 (0.50 g, 1.57 mmol) in a 1:1 mixture of pyridine and water (6 ml) at room temperature. The reaction was followed by TLC (9:1) dichloromethane/methanol and when no starting material remained, after about 8 h, the reaction mixture was neutralized with 2 M acetic acid. The mixture was evaporated, the resulting syrup was coevaporatedtwice with ethanol and the crude product was chromatographed on silica gel 60 using a gradient of dichloromethane/methanol (9:1-7:3) as eluent, giving the title compound (0.44 g, 95%). 1H NMR (CDsOD) 0 6.06 (1H, dd, J = 7.1 Hz, J = 3.9 Hz, 1-H), 1.78-2.52 (4H, rn, 2ab-H, 3ab-H), 4.19 (1H, m, J =4.6 Hz, J =6.9 Hz, 4-H), 3.03 (1H, dd, J =4.6 Hz, J = 13.3 Hz, 4a-H), 3.08 (1H, dd, J =6.9 Hz, J =13.3 Hz, 5b-H).Aryl unit; 0 7.45 (1 H, dd, J = 3.7 Hz, J = 1.2 Hz, 3-H Methyl N-[1,2,3,5-tetradeoxy-1f3-(5-(2 "-thienyl)-1 ,2,3,4-tetrahydro-2,4-dioxopyrimidin-1-yl) 
-furanos-5-yl] succinamate 5a
A solution of methyl succinyl chloride (51 mg, 0.34 rnrnol) (Adams and Ulich, 1920) in anhydrous THF (1.0 ml) was added dropwise to a solution of 4 (100 mg, 0.34 mmol) and triethylamine (50 Ill, 0.36 mmol) in anhydrous DMF (3.0 ml). After 1.5 h further triethylamine (20 Ill) and methyl succinyl chloride (10 mg, 0.07 mmol) were added. The reaction mixture was followed by TLC chloroform/methanol (9:1) and after 2.5 h the reaction was complete. The solvent was evaporated and the crude product was chromatographed on silica gel 60 using chloroform/methanol (9:1) as eluent. Further purification was achieved on HPLC using chloroform/2-propanoI99:1 as eluent, giving the title compound (57 mg, 41%). 1H NMR (CDCl s) 1) 6.08 (1 H, dd, J = 7.1 Hz, J = 3.9 Hz, 1-H), 1.67-2.54 (4H, m, 2ab-H, 3ab-H) Found; 408.1235. N-{1,2,3, 5-tetradeoxy-113 -(5-(2 "-thienyl)-1 ,2,3,4-tetrahydro-2,4-dioxopyrimidin-1-yl) 
furanos-5-yl] succinamic acid 5b
To a solution of Sa (40 mg, 0.098 mmol) in 50% aqueous methanol (7.5 ml) 1 M aqueous sodium hydroxide (196 Ill, 0.196 mmol) was added. The mixture was stirred at room temperature until no more starting material remained (TLC chloroform/methanol 9:1). The reaction mixture was then concentrated to about 2 ml and passed down a Dowex 50-x10 (1x4 cm) column. The eluted solution was evaporated to dryness and the resulting white solid was further dried in vacuo over phosphorus pentoxide at 50DC, giving the title compound (30 mg, 78%). 1H NMR (DMSO-d a) 1) 6.00 (1H, dd, J = 6.9 Hz, J = 4.0 Hz, 1-H), rn, 4.04 (1H, m, 3.40 (2H, m, 2.38 (4H, m, 2, 3, 2, 3, 
furanos-5-yl] fumaramate 6a
A solution of ethyl fumaryl chloride (55 mg, 0.34 mmol) (Schoenecker et al., 1986) in anhydrous THF (1.0 ml) was added dropwise to a solution of 4 (100 mg, 0.34 mmol) and triethylamine (50 Ill, 0.36 mmol) in anhydrous DMF (3.0 ml). The reaction mixture was followed by TLC chloroform/methanol (9:1) and after 2.5 h no starting material remained. The solvent was evaporated and the crude product was chromatographed on silica gel 60 using chloroform/methanol (9:1) as eluent. Further purification was achieved on HPLC using chloroform/2-propanol (97:3) as eluent, giving the title compound (74 mg, 52%). 1H NMR (CDCl s) 1) 6.00 (1H, dd, J = 7.4 Hz, J = 4.0 Hz, 1-H), 1.78-2.51 (4H, m, 2ab-H, 3ab-H), 4.25 (1H, m, 4-H 420.1229. Found; 420.1222. N-[1,2,3,5-tetradeoxy-113 -(5-(2' 'thienyl)-1 ,2,3,4-tetrahydro-2,4-deoxopyrimidin-1-yl) furanos-5-yl] fumaramic acid 6b
To a solution of 6a (36 mg, 0.086 mmol) in 50% aqueous methanol (7.0 ml) 1 M aqueous sodium hydroxide (172 Ill, 0.172 mmol) was added. The mixture was stirred at room temperature until no more starting material remained (TLC chloroform/methanol 9:1).The reaction mixture was then concentrated to about 2 ml and passed down a Dowex 50-x10 (1 x4 cm) column. The eluted solution was evaporated to dryness and the resulting white solid was further dried in vacuo over phosphorus pentoxide at 50 DC, giving the title compound 5'-Amino-2',3',5'-trideoxy-uridine (4) (30 mg, 0.10 mmol) was dissolved in pyridine (3.0 ml) and the solution was cooled to o DC. Maleic anhydride (9.8 mg, 0.10 mmol) was added with stirring. After 15 min the ice water bath was removed and the mixture was stirred until no starting material remained (the reaction mixture was followed by TLC dichloromethane/ methanol/acetic acid (12:2:1)). The reaction time was about 2 h. The pyridine was evaporated and the crude product was recrystallized from ethanol, giving the title compound (25 mg, 64%). 1H NMR (DMSO-d a) 
Materials and Experimental Procedures: Virology
The HIV-RT assay was performed as described previously (Zhang et al., 1993) . With activated calf thymus DNA as a template primer, dATP, dTTP and dCTP (17 11M each) were used as substrates, together with 3H-dGTP at a concentration close to the Km value. All assays were performed in duplicates.
